**Amendments To The Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**In the Claims:**

What is claimed is:

1. (Presently amened) A compound of formula (I):



(I)

wherein:
$R^1$ represents a group selected from:











each ring of which optionally ~~contains~~ includes a further heteroatom N,
Z represents an optional substituent halogen,
alk represents alkylene or alkenylene,
T represents S, O or NH;

$R^2$ represents hydrogen, -$C_{1-6}$alkyl, -$C_{1-3}$alkylCONR$^a$R$^b$, -$C_{1-3}$alkyl$CO_2C_{1-4}$alkyl, -$CO_2C_{1-4}$alkyl or -$C_{1-3}$alkyl$CO_2$H;

$R^a$ and $R^b$ independently represent hydrogen, -$C_{1-6}$alkyl, or together with the N atom to which they are bonded form a 5-, 6- or 7- membered non-aromatic heterocyclic ring optionally ~~containing~~ consisting of an additional heteroatom selected from O, N or $S(O)_n$, optionally substituted by -$C_{1-4}$alkyl~~, and optionally the S heteroatom is substituted by one or more O, i.e. and represents $S(O)_n$~~;

n represents 0-2;

X represents phenyl or a 5- or 6- membered aromatic heterocyclic group ~~containing~~ consisting of at least one heteroatom selected from O, N or S, each of which is optionally substituted by 0-2 groups selected from: halogen, -$C_{1-4}$alkyl, -$C_{2-4}$alkenyl, -CN, -$CF_3$, -NR$^a$R$^b$, -$C_{0-4}$alkylOR$^e$, -C(O)R$^f$ and -C(O)NR$^a$R$^b$;

$R^e$ represents hydrogen or -$C_{1-6}$alkyl;
$R^f$ represents -$C_{1-6}$alkyl;

Y represents phenyl or a 5- or 6- membered aromatic heterocyclic group ~~containing~~ consisting of at least one heteroatom selected from O, N or S, each of which is substituted by a group –$C_{1-2}$alkylNR$^c$R$^d$.

R$^c$ and R$^d$, together with the nitrogen atom to which they are bonded, form a 4-membered heterocyclic ring optionally substituted by halogen, OH or –$OC_{1-6}$alkyl, or a 5- or 6- membered non-aromatic heterocyclic ring substituted by OH, –$OC_{1-6}$alkyl or 1 to 2 halogens, with the proviso that the substituent is not attached to a ring carbon atom adjacent to a heteroatom;

~~and/~~or pharmaceutically acceptable derivative thereof.

2. (Original) A compound according to claim 1 wherein $R^1$ represents a group selected from:






each ring of which optionally ~~contains~~ includes a further heteroatom N,
Z represents an optional substituent halogen,
alk represents alkylene or alkenylene,
T represents S, O or NH;
~~and/~~or pharmaceutically acceptable derivative thereof.

3. (Currently amended) A compound according to claim 1 ~~or claim 2~~ wherein $R^2$ represents hydrogen ~~and/~~or pharmaceutically acceptable derivative thereof.

4. (Currently amended) A compound according to ~~any one of~~ claim~~s~~ 1-~~3~~ wherein X represents phenyl or a 5 or 6 membered aromatic heterocyclic group ~~containing~~ consisting of at least one heteroatom selected from O, N or S, each of which is optionally substituted by 0-2 groups selected from: halogen, -$C_{1-4}$alkyl or -$NR^aR^b$ ~~and/~~or pharmaceutically acceptable derivative thereof.

5. (Currently amended) A compound according to ~~any one of~~ claim~~s~~ 1-4 wherein Y represents a 5 or 6 membered aromatic heterocyclic group ~~containing~~ consisting of at least one heteroatom selected from O, N or S, each of which is substituted by a group -$CH_2NR^cR^d$ ~~and/~~or pharmaceutically acceptable derivative thereof.

6. (Currently Amended) A compound ~~according to claim 1~~ selected from:
(1*E*)-*N*-(1-{4-[2-(1-Azetidinylmethyl)-1*H*-imidazol-1-yl]-2-fluorophenyl}-2-oxo-3-pyrrolidinyl)-2-(5-chloro-2-thienyl)-1-propene-1-sulfonamide;
*N*-(1-{4-[2-(1-Azetidinylmethyl)-1*H*-imidazol-1-yl]-2-fluorophenyl}-2-oxo-3-pyrrolidinyl)-2-(5-chloro-2-thienyl)ethanesulfonamide;
*N*-((3*S*)-1-{4-[2-(1-Azetidinylmethyl)-1*H*-imidazol-1-yl]-2-fluorophenyl}-2-oxo-3-pyrrolidinyl)-6-chloro-1-benzothiophene-2-sulfonamide;
(*E*)-2-(5-Chloro-2-thienyl)-*N*-[1-(2-fluoro-4-{2-[(3-fluoro-1-pyrrolidinyl)methyl]-1*H*-imidazol-1-yl}phenyl)-2-oxo-3-pyrrolidinyl]ethenesulfonamide;
(1*E*)-2-(5-Chloro-2-thienyl)-*N*-[1-(2-fluoro-4-{2-[(3-fluoro-1-pyrrolidinyl)methyl]-1*H*-imidazol-1-yl}phenyl)-2-oxo-3-pyrrolidinyl]-1-propene-1-sulfonamide;

6-Chloro-*N*-[1-(2-fluoro-4-{2-[(3-fluoro-1-pyrrolidinyl)methyl]-1*H*-imidazol-1-yl}phenyl)-2-oxo-3-pyrrolidinyl]-1-benzothiophene-2-sulfonamide; and
6-Chloro-*N*-{1-[2-fluoro-4-(2-{[3-(methyloxy)-1-azetidinyl]methyl}-1*H*-imidazol-1-yl)phenyl]-2-oxo-3-pyrrolidinyl}-1-benzothiophene-2-sulfonamide formate; ~~and/~~or a pharmaceutically acceptable derivative thereof.

7. Cancelled.

8. (Currently amended) A pharmaceutical composition comprising a compound according to ~~any of~~ claims 1-~~6 and/~~or a pharmaceutically acceptable derivative thereof together with at least one pharmaceutical carrier ~~and/~~or excipient.

9. Cancelled.

10. (Original) A method of treating a patient suffering from a condition susceptible to amelioration by a Factor Xa inhibitor comprising administering a therapeutically effective amount of a compound according to ~~any of~~ claims 1-~~6 and/~~or a pharmaceutically acceptable derivative thereof.

11. (Original) A process for preparing a compound of formula (I) which comprises:

(a) reacting a compound of formula (II) or an acid addition salt thereof with a compound of formula (III) where V is a suitable leaving group:




(II)




(III)

OR:
(b) by reacting compounds of formula (I) where $R^2$ is hydrogen with compounds of formula (XI):

$$R^2—T \qquad (XI)$$

wherein $R^2$ is -$C_{1-6}$alkyl, -$C_{1-3}$alkylCONR$^a$R$^b$, -$C_{1-3}$alkylCO$_2$C$_{1-4}$alkyl, or -CO$_2$C$_{1-4}$alkyl and T is a suitable leaving group, optionally followed by removal of the alkyl protecting group where appropriate.